These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28281900)

  • 41. Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era.
    Roukos DH; Ziogas DE; Papaloukas C; Baltogiannis G
    Future Oncol; 2012 Nov; 8(11):1373-6. PubMed ID: 23148609
    [No Abstract]   [Full Text] [Related]  

  • 42. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
    Sen K; Banerjee S; Mandal M
    Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer.
    Song R; Gu D; Zhang L; Zhang X; Yu B; Liu B; Xie J
    Mol Carcinog; 2018 Nov; 57(11):1608-1615. PubMed ID: 30074279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
    Götze S; Coersmeyer M; Müller O; Sievers S
    Int J Oncol; 2014 Oct; 45(4):1715-23. PubMed ID: 25050608
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiogenesis in Colorectal Cancer: Antibodies.
    Chan E
    Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A null mutation in TNIK defines a novel locus for intellectual disability.
    Anazi S; Shamseldin HE; AlNaqeb D; Abouelhoda M; Monies D; Salih MA; Al-Rubeaan K; Alkuraya FS
    Hum Genet; 2016 Jul; 135(7):773-8. PubMed ID: 27106596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
    Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
    Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aurora A: target invalidated?
    Cochran AG
    Chem Biol; 2008 Jun; 15(6):525-6. PubMed ID: 18559262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer.
    Tan YJ; Lee YT; Yeong KY; Petersen SH; Kono K; Tan SC; Oon CE
    Future Med Chem; 2018 Sep; 10(17):2039-2057. PubMed ID: 30066578
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug development: Mix and match.
    Scudellari M
    Nature; 2015 May; 521(7551):S12-4. PubMed ID: 25970452
    [No Abstract]   [Full Text] [Related]  

  • 52. [Synergistic effect of rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells].
    Zhang YJ; Fang JY; Sun DF; Zhao SL; Shen GF; Zheng Q; Zhu HY
    Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):889-93. PubMed ID: 18478925
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aurora kinases dawn as cancer drug targets.
    Sausville EA
    Nat Med; 2004 Mar; 10(3):234-5. PubMed ID: 14991042
    [No Abstract]   [Full Text] [Related]  

  • 54. Therapeutic Potential of Targeting Wnt/β-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress.
    Bahrami A; Amerizadeh F; ShahidSales S; Khazaei M; Ghayour-Mobarhan M; Sadeghnia HR; Maftouh M; Hassanian SM; Avan A
    J Cell Biochem; 2017 Aug; 118(8):1979-1983. PubMed ID: 28109136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Revisiting the frontiers of pharmacogenomics of colon cancer.
    Falandry C; Bonnefoy M; Freyer G
    Pharmacogenomics; 2011 Sep; 12(9):1243-8. PubMed ID: 21919602
    [No Abstract]   [Full Text] [Related]  

  • 56. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.
    Pandurangan AK
    Asian Pac J Cancer Prev; 2013; 14(4):2201-5. PubMed ID: 23725112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Colorectal cancer stem cells as biomarkers: where it all starts?
    Avital I; Summers TA; Steele SR; Waldman S; Nissan A; Bilchik AJ; Protic M; Man YG; Brücher BL; Stojadinovic A
    J Surg Oncol; 2013 Jun; 107(8):791-3. PubMed ID: 23512573
    [No Abstract]   [Full Text] [Related]  

  • 59. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
    Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
    Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.